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Abstract
Internally Gd doped mesoporous nanoparticles have been prepared and exhibit unprecedented 
relaxivities that are retained on external biomodification. In tuning diffusive water access, image 
contrast can be reversibly switched in the presence of a specific protein target.
Among the spatially resolved clinical imaging modalities now available, magnetic resonance 
imaging (MRI) remains the most convenient and widely used of those which are non-
invasive.1 During the past decade a great deal of progress has been made in enhancing the 
natively low image contrast available within protic MRI relaxivity with molecular, 
biological or nanoparticle based formulations based on chelated gadolinium, through 
aggregation/rotation based changes or alterations in metal hydration number.1,2 Such 
attempts include those which are biovectorable and thus capable of identifying and reporting 
on specific physiology and pathology.3-11 A range of 1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and diethylenetriaminepentaacetic 
acid (DTPA) derivatives have, for example, been bound to peptides, monoclonal antibodies 
or proteins capable of targeting specific cell receptors.3,4,12
Mesoporous silica nanoparticles (MSNs) offer much potential to both high contrast imaging 
and the delivery of therapeutics and can be chemically modified with relative ease.13-17 
Indeed, the chemical capping of MSNs has been investigated as a means of triggering drug 
delivery.18 Particles <200 nm in size are generally believed to be able to avoid 
reticuloendothdlial system (RES),19,20 an ability greatly aided through the use of masking 
hydrophilic coatings (e.g. polyethylene glycol; PEG).21 To date, there exist several 
examples of doped MSNs capable of generating marked T1 or T2 contrast.2,22 Notably, 
although central to any targetted imaging application, the effects of particle biomodification 
on this have not previously been considered. Since the diffusive access of water through 
particle nanopores to internalised magnetic elements is both theoretically expected23,24 and 
experimentally25,26 verified to underpin T1 relaxivity (and thus image contrast), the initial 
motivation of this work was to generate <100 nm pegylated and biomodified nanoparticles 
with retained internal water access and high relaxivity. The ability of an external protein to 
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selectively respond to specific partner proteins in solution was subsequently used to gate 
image contrast.
Silica nanoparticles are generally believed to be non-toxic in vitro and in vivo.27 To avoid 
the known toxic risk associated with free Gd3+,28 kinetically inert Gd–DOTA complexes 
were utilised herein.29 We have previously demonstrated that the covalent tethering of these 
macrocycles to MSNs can be achieved with negligible Gd loss over a 4 week period30 (also 
see below). The appendage of paramagnetic centres to MSNs instills not only advantages 
associated with increased rotational correlation time,11 but also those engendered by the 
high surface area and water access features of a mesoporous scaffold,23,25,26 yielding 
constructs with markedly high relaxivity.24,25,30 In order to maximise the sensitivity of this 
to processes occurring on the outer surface of the particles we have biased the location of 
covalently bound Gd–DOTA internally (a space likely to be associated with restricted water 
mobility, increased diffusional (τD) and rotational (τR) correlation times and altered water 
proton residence lifetime (τm)31-34) through the use of a modified co-condensation 
procedure.30,35 This methodology generates imaging agents with extraordinarily high 
relaxivities30 (Fig. S1, ESI†).
Transmission Electron Microscope (TEM; Fig. 1 and Fig. S3, ESI†), dynamic light 
scattering (DLS; Fig. S2a, ESI†) and BET (Brunauer-Emmett-Teller; Fig. S2c, ESI†) surface 
area analysis data confirmed the native Gd doped MSNs (Gd–DOTA MSNs) to be well 
dispersed with a particle diameter of 75.9 ± 6.4 nm, hydrodynamic size of 138.7 nm (PDI: 
0.09) and pore sizes of 3.2 ± 1.3 nm. Subsequent external surface modifications were 
conducted via the stepwise post-grafting of PEG layers (PEG5000 and PEG2000), a process 
monitored through associated changes in zeta potential (Fig. S2d, ESI†). The assessments 
confirmed these procedures to be highly reproducible and associated with negligible 
perturbation of particle stability/dispersion or size (Fig. S2a and S3, ESI†). Importantly, 
these surface modifications could also be achieved with negligible loss of MR relaxivity 
(Fig. S4a, ESI†), observations consistent with the high entropy, low packing density and 
water penetration characteristics of such layers. The effectiveness of subsequent protein 
modification in mediating clean particle vectoring to target proteins was analyzed in a 
microarray format on modified glass chips (Fig. S5, ESI†).
In seeking to analyse the effects of biomodification on particle MR contrast characteristics 
one may, in the first instance, consider the effects of the biomolecular layer on particle 
rotational correlation time τc (s) according to τc = (4πηr3)/3kT where r is radius, η the 
solvent viscosity, (8.94 × 10−4 kg m−1 s−1 for H2O at 298 K), and kT its usual meaning.23 
Herein, a ~6 nm biomolecular coat (BSA)36 is expected to generate a negligible percentage 
change in τc (from ~3 × 104 ns to 9 × 104 ns).
Significantly, particle relaxivity can be tuned through the use of variable length spacer 
sitting between the natively hydroxylated surface and the anchored protein (Fig. 2). 
Specifically, the direct anchoring of BSA through a short linker (3-aminopropyl)-
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triethoxysilane (APTES) leads to a 78.5 ± 1.5% drop in relaxivity, a reproducible 
observation we assign to the steric capping of particle pores and thus heavily restricted 
diffusional water access to internalised Gd centres. In inserting a PEG5000 spacer between 
the particle and protein, vectoring is enabled with retention of high relaxivity (78.0 ± 6.0% 
of the non protein capped particle; Fig. 2).37 Interestingly, the use of a shorter PEG2000 
spacer leads to a reduced recovery of relaxivity (14.90 ± 0.56 mM−1 s−1, 67.5 ± 5.5% of 
native value), an observation reflective of its inability to robustly keep the protein coat 
(tethered or otherwise) away from the particle pores (Fig. 2).
We have subsequently sought to use this steric gating in fabricating nanoparticles for which 
image contrast is reversibly switched by the presence or absence of a protein partner (Fig. 
3). In establishing this proof of principal we have utilised the steric bulk of streptavidin 
(STV, 5 nm38 > particle pore size, 3.2 ± 1.3 nm). In the first instance native Gd–DOTA 
doped MSNs were biotin modified with retention of facile water access (see detailed 
experimental procedures in ESI†). In the presence of low molar equivalents of streptavidin 
such particles could be robustly capped without aggregation or significant increase in 
resolved particle hydrodynamic radius39-41 (see Fig. S1b, ESI†) but a dramatic (>60%) 
decrease in relaxivity (Fig. 3). The colloidal and relaxivity characteristics of these capped 
particles are unchanged through three months of storage in water (see Fig. S4c, ESI†), the 
latter observation, made after particle washing and centrifugation, being consistent with 
negligible leakage of Gd (the gating characteristics referred to below are also retained at 3 
months).
In confirming the specificity of this image contrast capping, the relaxivity characteristics of 
biotinylated Gd-doped MSNs were unchanged in the presence of molecular biotin, biotin 
saturated STV or natively unmodified BSA (Fig. S4b, ESI†). Though the solution phase 
affinity of biotin for STV is very high,38 a substantial size dependent decrease in this at 
nanoparticle surfaces has been previously noted as has the competitive displacement of STV 
by solution phase biotin.38,41,42 In the presence of 1000 fold excess (7 μM) of biotinylated 
BSA, the gating STV is displaced and particle relaxivity recovers to 84.5 ± 8.5% of its 
original value) (Fig. 3). [Note that, because of the very low biotin coverages (<1 biotin unit 
per 1000 nm2 of particle surface) employed in this work, we do not expect potentially 
displacement hindering multivalent/local concentration effects.]42-44
In conclusion, the synthesis of colloidally stable, protein capped and vectoring Gd doped 
MSNs is reported herein. Through appropriate surface chemistry, these can be externally 
modified without detrimental loss of very high relaxivity (39.26 ± 1.29 mM−1 s−1 at 3 T, 
unprecedented for nanoparticles based on a silica scaffold).30,45 Significantly, the Gd 
loading can be internally biased at the point of synthesis such that diffusive water access, 
and hence MR contrast, can be sterically gated at the particle periphery. While the 
integration of suitably long PEG spacers enables protein conjugation to be achieved with 
retention of an “open gate”, conjugation with short spacers dramatically reduces relaxivity. 
In the presence of solution phase protein partners these sterically bulky protein gates are 
competed off and high image contrast returns. Though there exist examples of paramagnetic 
contrast agents for which contrast has been ionically or biologically tuned through a change 
in hydration number or rotational correlation time (see Table S1, ESI†), the work herein not 
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only identifies and utilises the importance of water access, but also constitutes the first 
example of reversible T1 contrast gating exploiting protein recognition. This proof of 
principal, and an array of potential derivatives, is of significant potential value in furthering 
the application of nanoparticle chemistry to functional MR imaging.
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Fig. 1. 
TEM image of representative protein capped Gd–DOTA MSNs (75.9 ± 6.4 nm in diameter; 
scale bar 50 nm). The schematics depict the native pegylated (left) and sterically capped 
(right) water access to internalised Gd–DOTA units.
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Fig. 2. 
Schematic summary of particle relaxivity tuning through surface chemistry. Non protein 
capped Gd–DOTA MSNs have open pores, good water accessibility and relaxivities of 
22.25 ± 0.83 mM−1 s−1 in water; the direct anchoring of BSA via a short silane linker leads 
to a dramatic reduction in relaxivity (4.74 ± 0.18 mM−1 s−1); in buffering this 
biomodification away from the surface with a linker, high relaxivity is recovered (14.90 ± 
0.56 mM−1 s−1 for PEG2000, 17.34 ± 0.65 mM−1 s−1 for PEG5000). Error bars here 
represent cumulative errors arising from triple repeats of relaxivity assessment (across at 
least three different sample concentrations at 7 T and 20 °C) and ICP quantification.
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Fig. 3. 
Schematic summary of MSN relaxivity gating. Externally biotinylated Gd-doped MSNs 
enjoy good water accessibility and a high relaxivity (15.07 ± 0.57 mM−1 s−1) that can be 
reversibly capped by the steric bulk of a bound STV (5.83 ± 0.22 mM−1 s−1; <40% of the 
original value). In the presence of low μM biotinylated BSA, the gating protein is competed 
off the particle surface and relaxivity recovers to 12.67 ± 0.71 mM−1 s−1 (84.5 ± 8.5% of 
original value). Error here represents cumulative error arising from triple repeats of 
relaxivity assessment (across at least three different sample concentrations at 7 T and 20 °C) 
and ICP quantification.
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